Halozyme COVID-19 Response
Homepage

Science

ENHANZE® Technology

HYLENEX® recombinant

(hyaluronidase human injection)

Careers

Investors

About Us

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

July 12, 2021 Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
June 22, 2021 Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma
June 22, 2021 ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Copyright© 2015-2019. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.56.0.1

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok